Skye acquires Bird Rock Bio, weeks after Novo Nordisk says it will buy a CB1 developer
Skye Bioscience acquired Bird Rock Bio to get its hands on an asset targeting CB1 just two weeks after Novo Nordisk dipped its toes into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
